#1 Clinical Trials Search in Europe

Explore popular drugs in clinical trials

Check which drugs are currently being frequently studied.

See also our rare diseases glossary and popular diseases list.

Starting by letter

To open the drugs glossary, select a letter from the list below.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All drugs

Most popular drugs

The list below features the most popular substances currently involved in ongoing clinical trials.

Drug Trials
Pembrolizumab 446
Sodium Chloride 411
Carboplatin 337
Cisplatin 282
Paclitaxel 250
Fluorouracil 232
Oxaliplatin 223
Nivolumab 209
Dexamethasone 204
Rituximab 194
Cyclophosphamide 186
Bevacizumab 161
Durvalumab 161
Capecitabine 156
Paracetamol 155
Atezolizumab 146
Docetaxel 128
Prednisone 127
Tocilizumab 124
Prednisolone 121
Gemcitabine 117
Venetoclax 116
Pemetrexed 114
Mycophenolate Mofetil 114
Etoposide 114
Doxorubicin Hydrochloride 108
Infliximab 98
Lenalidomide 98
Ipilimumab 90
Folinic Acid 89
Acetylsalicylic Acid 88
Semaglutide 88
Paclitaxel Albumin-Bound 84
Placebo 84
Cytarabine 79
Daratumumab 79
Calcium Folinate 78
Methotrexate 78
Fludarabine Phosphate 77
Letrozole 72
Bortezomib 71
Olaparib 70
Gemcitabine Hydrochloride 69
Obinutuzumab 67
Dapagliflozin 66
Azacitidine 66
Trastuzumab 65
Cetuximab 64
Tacrolimus 63
Fulvestrant 62
Lenvatinib 62
Methylprednisolone 61
Irinotecan 61
Irinotecan Hydrochloride Trihydrate 59
Temozolomide 59
Cemiplimab 57
Vincristine Sulfate 57
Trastuzumab Deruxtecan 53
Enzalutamide 51
Lidocaine Hydrochloride Monohydrate 50
Apixaban 50
Betamethasone Sodium Phosphate 50
Dexamethasone Sodium Phosphate 49
Codeine Phosphate 49
Amoxicillin 47
Buclizine Hydrochloride 47
Lidocaine Hydrochloride 46
Exemestane 46
Potassium Chloride 46
Empagliflozin 46
Hydrocortisone 45
Anastrozole 45
Adalimumab 45
Ribociclib 44
Doxorubicin 43
Pertuzumab 43
Clopidogrel 42
Oxygen 42
Clavulanic Acid 42
Pomalidomide 42
Tenofovir Alafenamide 41
Ruxolitinib 41
Ibrutinib 41
Rivaroxaban 41
Abemaciclib 40
Atorvastatin 40
Ropivacaine Hydrochloride 40
Sulfamethoxazole 39
Bendamustine Hydrochloride 39
Carfilzomib 39
Trimethoprim 39
Pemetrexed Disodium 38
Propofol 38
Palbociclib 38
Linezolid 38
Metformin Hydrochloride 38
Ifosfamide 38
Cyclophosphamide Monohydrate 37
Dexamethasone Acetate 37
Emtricitabine 37

New drugs in trials

The list below features the new substances involved to ongoing clinical trials.

#1 VMX-C001

Clinical trials are studying VMX-C001 in people who take a Factor Xa direct oral anticoagulant and need urgent surgery or another high-bleeding-risk procedure.

4 weeks ago
#2 LIPASE

Clinical trials are investigating LIPASE, including a new lipase product compared with pancrelipase.

4 weeks ago
#3 TRIACYLGLYCEROL LIPASE

Clinical trials of TRIACYLGLYCEROL LIPASE are studying a new lipase treatment in adults with exocrine pancreatic insufficiency.

4 weeks ago
#4 IMA401

Clinical trials are investigating IMA401 in patients with recurrent and/or refractory solid tumors.

4 weeks ago
#5 ALLERGEN EXTRACTS

Clinical trials are studying BLOMIA TROPICALIS POLYMERIZED EXTRACT as part of a vaccine for dust mite and Blomia tropicalis allergy.

4 weeks ago
#6 AUR200

Clinical trials are investigating AUR200 in people with generalized myasthenia gravis.

4 weeks ago

Drugs starting by s

  • 1 

    Sxr1096

    ,

    A groundbreaking clinical trial is underway to assess the effectiveness of SXR1096, a new topical cream designed to treat Netherton Syndrome. This rare inflammatory skin condition currently lacks specific treatments, making this study a potential game-changer for patients. The trial aims to evaluate the safety and efficacy of SXR1096 cream compared to a placebo in adults and adolescents with Netherton Syndrome over a four-week treatment period.

    Related diseases and areas:

  • 1 

    Sym023

    ,

    Sym023 is an innovative antibody being studied in clinical trials for the treatment of advanced solid tumors and lymphomas. This article explores the ongoing research into Sym023, its potential benefits, and its role in combination therapies for patients with difficult-to-treat cancers. We’ll examine the key findings from current clinical trials and what they mean for the future of cancer treatment.

    Related diseases and areas:

  • 1 

    Sym024

    ,

    A groundbreaking clinical trial is underway to investigate the potential of Sym024, an anti-CD73 antibody, in treating advanced solid tumor malignancies. This study aims to evaluate the safety and effectiveness of Sym024 both as a standalone treatment and in combination with Sym021, an anti-PD-1 antibody. The trial focuses on patients with metastatic cancer and solid tumors, offering hope for new treatment options in the fight against these challenging conditions.

    Related diseases and areas:

  • 2 

    Sym025

    , ,

    Sym025, also known as S095029, is an innovative anti-NKG2A antibody currently being studied in clinical trials for the treatment of advanced cancers. This article will provide an overview of the ongoing research involving Sym025, focusing on its potential applications in gastroesophageal junction/gastric cancer and non-small cell lung cancer (NSCLC). We’ll explore the objectives, eligibility criteria, and potential benefits of these trials, offering valuable insights for patients and healthcare professionals alike.

    Related diseases and areas:

  • 2 

    Syn2

    ,

    SYN2 is an innovative 18F-labelled tracer being studied in clinical trials for its potential in diagnosing coronary artery disease (CAD). These trials aim to evaluate the effectiveness of SYN2 in Positron Emission Tomography (PET) imaging for patients with suspected heart conditions. The studies focus on assessing the diagnostic performance, safety, and ability to quantify myocardial blood flow using SYN2 PET imaging.

    Related diseases and areas:

  • 1 

    Syn321

    ,

    A new drug called SYN321 is currently being studied in clinical trials for the treatment of knee osteoarthritis. This innovative medication is administered through intra-articular injections directly into the knee joint. The ongoing research aims to evaluate the safety, tolerability, and potential effectiveness of SYN321 in providing relief for patients suffering from this common and often debilitating condition.

    Related diseases and areas:

  • 7 

    Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues

    , , ,

    This article summarizes several clinical trials investigating the use of plozasiran, also known as ARO-APOC3, for treating hypertriglyceridemia. Plozasiran is a novel drug that targets apolipoprotein C-III mRNA to reduce triglyceride levels in the blood. The trials aim to evaluate the safety and efficacy of plozasiran in patients with varying degrees of hypertriglyceridemia, including severe cases and those with familial chylomicronemia syndrome.

    Related diseases and areas:

  • 1 

    Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Tmprss6 Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues

    ,

    This article discusses the clinical trials of SLN124, a novel drug being studied for the treatment of Polycythemia Vera (PV). SLN124 is a synthetic double-stranded siRNA oligonucleotide that targets TMPRSS6 mRNA and is linked to a ligand containing three N-acetylgalactosamine residues. The trials aim to assess the safety, efficacy, and potential benefits of SLN124 in managing PV symptoms and reducing the need for phlebotomies in patients with this condition.

    Related diseases and areas: